Ready for your all-in-one single cell sequencing solution?

B2B-RARE Bench to Bedside: Understanding and Personalizing Treatment for Rare Neuromuscular Diseases

In the European Union alone, around 36 million people live with a rare disease. And that number sounds almost contradictory.

How can something rare affect so many people?

The answer is that there isn’t just one rare disease. There are between 6,000 and 8,000 distinct conditions that fall into this category, and of these, about 500 are rare neuromuscular diseases affecting roughly half a million people across the European Union.

Watch this webinar to get an inside look at how B2B-RARE is advancing personalized therapies for rare neuromuscular diseases, combining #transcriptomics, #proteomics, #metabolomics, #bioinformatics, and #AI-driven analysis.

📌 To learn more about the project and get in touch with the team, visit: https://b2b-rare.de

📌 Have a single cell project in mind? Get in touch with us at https://singleron.bio/contact-us/ to learn how we can support you.